SCHEMBL1685151

SCHEMBL1685151

CCN1CCN(C(=O)c2ccc(Nc3ccc(-c4ccc5c(c4)C=NC5=O)n4ccnc34)cc2)CC1

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CCND1 P24385 3/20 0.39
CDK6 Q00534 3/20 0.39
CDK4 P11802 1/20 0.39
CCND3 P30281 1/20 0.39
CCNT1 O60563 2/20 0.36
CDK9 P50750 2/20 0.36
MAPKAPK2 P49137 1/20 0.36
EGLN1 Q9GZT9 1/20 0.36
ADORA2A P29274 2/20 0.35
ADORA1 P30542 2/20 0.35
SYK P43405 3/20 0.35
LRRK2 Q5S007 1/20 0.35
RIPK1 Q13546 2/20 0.35
BTK Q06187 1/20 0.34
ALDH1A1 P00352 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
DYRK2 Q92630 1/20 0.34
MAPKAPK5 Q8IW41 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1685336 0.91 JAK1 (0.35) MAPKAPK2LRRK2RIPK1
SCHEMBL1685123 0.90 MAPKAPK2 (0.34) CCND1CDK6CDK4CCND3CCNT1
SCHEMBL1685148 0.89 HRH3 (0.38) CCND1CDK6CDK4CCNT1CDK9
SCHEMBL1685204 0.88 RIPK1 (0.43) CCND1CDK6CDK4CCND3CCNT1
SCHEMBL1685154 0.86 MAPKAPK5 (0.48) CCND1CDK6CDK4CCND3MAPKAPK2
SCHEMBL12618767 0.86 MAPKAPK5 (0.47) CCND1CDK6CDK4CCND3CCNT1
SCHEMBL1685173 0.85 MKNK1 (0.43) ALDH1A1
SCHEMBL3881243 0.84 CDK1 (0.39) EGLN1
SCHEMBL10166437 0.80 CCND1 (0.37) CCND1CDK6CDK4CCND3CCNT1
SCHEMBL1685319 0.78 JAK2 (0.36) MAPKAPK5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120010206-A1 IMIDAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES GALAPAGOS N. V. (BE) 2012-01-12 US disclosed
US-20090048245-A1 Imidazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases GALAPAGOS NV (BE) 2009-02-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120010206-A1 IMIDAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES COL2A1, MMP1, COL1A1 CCND1 1362/4885CDK6 359/4885CDK4 167/4885
US-20090048245-A1 Imidazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases COL2A1, MMP1, COL1A1 CCND1 1362/4885CDK6 359/4885CDK4 167/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.